See all treatments in the PatientsLikeMe system shared by patients just like you.
Brand Names:
Pamelor, Norpress, APO-Nortriptyline
What is Nortriptyline? Nortriptyline is a tricyclic antidepressant used in the treatment of depression. Off label it is used for chronic pain, anxiety disorders, bedwetting in children, attention-deficit/hyperactivity disorder (ADHD); and as an adjunctive therapy for smoking cessation.
See more information, including instructions, precautions, side effects, and interactions.
232 patients in the community are taking or have taken Nortriptyline.
Top 10 (Show all)
| Reason | # Patients | Percentage of patients |
|---|---|---|
| Depression | 34 | 14% |
| Pain | 29 | 12% |
| Other | 28 | 12% |
| Treat my mood condition(s) | 15 | 6% |
| Sleeplessness | 14 | 6% |
| Migraine Headaches | 10 | 4% |
| Aching/Burning/Throbbing/Buzzing tendon body pain | 9 | 3% |
| Anxiety | 7 | 3% |
| Nerve pain (neuropathic pain) | 6 | 2% |
| Awakening due to pain | 5 | 2% |
| Support another treatment | 3 | 1% |
| Excess saliva | 3 | 1% |
| Emotional lability | 3 | 1% |
| Migraine | 3 | 1% |
How long current patients have been taking Nortriptyline or how long patients were taking Nortriptyline before stopping.
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Did not seem to work | 29 | 40% | |
| Side effects too severe | 25 | 35% | |
| Doctor's advice | 20 | 28% | |
| Other | 15 | 21% | |
| Personal research | 4 | 6% | |
| Not indicated | 4 | 6% | |
| Expense | 3 | 4% | |
| Course of treatment ended | 2 | 3% |
Results from 35 patient evaluations. See the overall results and all individual evaluations.
| Major | 60% | 3 |
|---|---|---|
| Moderate | 40% | 2 |
Other
| Severe | 14% | 5 |
|---|---|---|
| Moderate | 17% | 6 |
| Mild | 29% | 10 |
| None | 40% | 14 |
Top reported side-effects include: dry mouth, Weight gain, Hnag over effect
Summary results are based on 35 individual responses. For more information, see overall results for Adherence, Burden and Cost.
Report created on November 07, 2009.